The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release

Brain, Behavior, and Immunity

Volumn 23, Issue 4, 2009, Pages 492-497

  Bland, Sondra T ^a   Hutchinson, Mark R ^b   Maier, Steven F ^a   Watkins, Linda R ^a   Johnson, Kirk W ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Avigen Inc   (United States)

Author keywords

Dopamine; Morphine; Nucleus accumbens; Opioid; Withdrawal

Indexed keywords

DOPAMINE; IBUDILAST; MORPHINE; NALOXONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG DOSE ESCALATION; GLIA; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAPERITONEAL; MALE; MICRODIALYSIS; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEUROGLIA; NUCLEUS ACCUMBENS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 63249099886     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2009.01.014     Document Type: Article

References (48)

1. Araque A., Parpura V., Sanzgiri R.P., and Haydon P.G. Glutamate-dependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. Eur. J. Neurosci. 10 (1998) 2129-2142
2. Araque A., Parpura V., Sanzgiri R.P., and Haydon P.G. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22 (1999) 208-215
3. Banati R.B. Brain plasticity and microglia: is transsynaptic glial activation in the thalamus after limb denervation linked to cortical plasticity and central sensitisation?. J. Physiol. Paris 96 (2002) 289-299
4. Bland S.T., Twining C., Schmid M.J., Der-Avakian A., Watkins L.R., and Maier S.F. Stress potentiation of morphine-induced dopamine efflux in the nucleus accumbens shell is dependent upon stressor uncontrollability and is mediated by the dorsal raphe nucleus. Neuroscience 126 (2004) 705-715
5. Compton W.M., and Volkow N.D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 81 (2006) 103-107
6. De Vries T.J., Schoffelmeer A.N., Binnekade R., and Vanderschuren L.J. Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration. Psychopharmacology (Berl.) 143 (1999) 254-260
7. Di Chiara G., and Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr. Opin. Pharmacol. 7 (2007) 69-76
8. Dyke H.J., and Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs 11 (2002) 1-13
9. Fdez Espejo E., Cador M., and Stinus L. Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: a newly-developed "etho-score". Psychopharmacology (Berl.) 122 (1995) 122-130
10. Fitzgerald L.W., Ortiz J., Hamedani A.G., and Nestler E.J. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J. Neurosci. 16 (1996) 274-282
11. Gellert V.F., and Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 205 (1978) 536-546
12. Gholami A., Zarrindast M.R., Sahraei H., and Haerri-Rohani A. Nitric oxide within the ventral tegmental area is involved in mediating morphine reward. Eur. J. Pharmacol. 458 (2003) 119-128
13. Hamdy M.M., Mamiya T., Noda Y., Sayed M., Assi A.A., Gomaa A., Yamada K., and Nabeshima T. A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice. Behav. Brain Res. 118 (2001) 85-93
14. Harris G.C., and Aston-Jones G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 371 (1994) 155-157
15. Hutchinson M.R., Bland S.T., Johnson K.W., Rice K.C., Maier S.F., and Watkins L.R. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci. World J. 7 (2007) 98-111
16. Hutchinson, M.R., Lewis, S.S., Coats, B.D., Skyba, D.A., Crysdale, N.Y., Berkelhammer, D.L., Brzeski, A., Northcutt, A., Vietz, C.M., Judd, C.M., Maier, S.F., Watkins, L.R., Johnson, K.W., 2009. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav. Immun. 23, 240-250.
17. Hyman S.E., Malenka R.C., and Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci. 29 (2006) 565-598
18. Itoh A., Noda Y., Mamiya T., Hasegawa T., and Nabeshima T. A therapeutic strategy to prevent morphine dependence and tolerance by coadministration of cAMP-related reagents with morphine. Methods Find. Exp. Clin. Pharmacol. 20 (1998) 619-625
19. Iyo M., Bi Y., Hashimoto K., Inada T., and Fukui S. Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram. Eur. J. Pharmacol. 312 (1996) 163-170
20. Laschka E., Teschemacher H., Mehraein P., and Herz A. Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas. Psychopharmacologia 46 (1976) 141-147
21. Ledeboer A., Hutchinson M.R., Watkins L.R., and Johnson K.W. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs 16 (2007) 935-950
22. Li X.X., Nomura T., Aihara H., and Nishizaki T. Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci. 68 (2001) 1343-1350
23. Madelian V., and La Vigne E. Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells. Biochem. Pharmacol. 51 (1996) 1739-1747
24. Mamiya T., Noda Y., Ren X., Hamdy M., Furukawa S., Kameyama T., Yamada K., and Nabeshima T. Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor. Br. J. Pharmacol. 132 (2001) 1111-1117
25. Menniti F.S., Faraci W.S., and Schmidt C.J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5 (2006) 660-670
26. Mika J., Wawrzczak-Bargiela A., Osikowicz M., Makuch W., and Przewlocka B. Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav. Immun. 23 (2009) 75-84
27. Narita M., Miyatake M., Shibasaki M., Shindo K., Nakamura A., Kuzumaki N., Nagumo Y., and Suzuki T. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 31 (2006) 2476-2488
28. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
29. Pothos E., Rada P., Mark G.P., and Hoebel B.G. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res. 566 (1991) 348-350
30. Raghavendra V., Tanga F.Y., and DeLeo J.A. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29 (2004) 327-334
31. Saud B., Nandi J., Ong G., Finocchiaro S., and Levine R.A. Inhibition of TNF-alpha improves indomethacin-induced enteropathy in rats by modulating iNOS expression. Dig. Dis. Sci. 50 (2005) 1677-1683
32. Schubert P., Morino T., Miyazaki H., Ogata T., Nakamura Y., Marchini C., and Ferroni S. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. NY Acad. Sci. 903 (2000) 24-33
33. Sebastiani G., Morissette C., Lagace C., Boule M., Ouellette M.J., McLaughlin R.W., Lacombe D., Gervais F., and Tremblay P. The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation. Neurobiol. Aging 27 (2006) 691-701
34. Si Q., Nakamura Y., Ogata T., Kataoka K., and Schubert P. Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 812 (1998) 97-104
35. Sparrow J.R. Inducible nitric oxide synthase in the central nervous system. J. Mol. Neurosci. 5 (1994) 219-229
36. Stella L., De Novellis V., Vitelli M.R., Mazzeo F., Berrino L., Rossi F., and Fillippelli A. Interactive role of adenosine and dopamine in the opiate withdrawal syndrome. Naunyn Schmiedebergs Arch. Pharmacol. 368 (2003) 113-118
37. Streit W.J., Walter S.A., and Pennell N.A. Reactive microgliosis. Prog. Neurobiol. 57 (1999) 563-581
38. Suzumura A., Ito A., Yoshikawa M., and Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 837 (1999) 203-212
39. Thompson B.E., Sachs B.D., Kantak K.M., and Cherry J.A. The type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice. Eur. J. Neurosci. 19 (2004) 2561-2568
40. Tzeng S.F., Hsiao H.Y., and Mak O.T. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr. Drug Targets Inflamm. Allergy 4 (2005) 335-340
41. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 12 (2007) 227-462
42. van Calker D., and Biber K. The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders. Neurochem. Res. 30 (2005) 1205-1217
43. Watkins L.R., Hutchinson M.R., Johnston I.N., and Maier S.F. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 28 (2005) 661-669
44. Watkins L.R., Hutchinson M.R., Ledeboer A., Wieseler-Frank J., Milligan E.D., and Maier S.F. Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav. Immun. 21 (2007) 131-146
45. Wise R.A. Opiate reward: sites and substrates. Neurosci. Biobehav. Rev. 13 (1989) 129-133
46. Wise R.A., and Bozarth M.A. Brain mechanisms of drug reward and euphoria. Psychiatr. Med. 3 (1985) 445-460
47. Wu Y.N., Mercuri N.B., and Johnson S.W. Presynaptic inhibition of gamma-aminobutyric acidB-mediated synaptic current by adenosine recorded in vitro in midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 273 (1995) 576-581
48. Yan Y., Nitta A., Mizuno T., Nakajima A., Yamada K., and Nabeshima T. Discriminative-stimulus effects of methamphetamine and morphine in rats are attenuated by cAMP-related compounds. Behav. Brain Res. 173 (2006) 39-46